Astegolimab
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research[1][2][3].
Product Specifications
CAS Number
2173054-79-8
Product Name Alternative
MSTT 1041A; RG 6149
UNSPSC
12352203
Target
Interleukin Related; MDM-2/p53; NF-κB
Type
Inhibitory Antibodies
Related Pathways
Apoptosis; Immunology/Inflammation; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/astegolimab.html
Purity
99.00
Solubility
H2O
Smiles
[Astegolimab]
Molecular Weight
(144.98 kDa)
References & Citations
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
IL-33
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
